UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Embedding Patient Input in Outcome Measures for Long‐Term Disease‐Modifying Parkinson Disease Trials

Movement disorders, 2024-02, Vol.39 (2), p.433-438

2024

Volltextzugriff (PDF)

An International Multi-Stakeholder Delphi Survey Study on the Design of Disease Modifying Parkinson’s Disease Trials

Journal of Parkinson's disease, 2023-01, Vol.13 (8), p.1343-1356

2023

Volltextzugriff (PDF)

Incorporating usability evaluation into iterative development of an online platform to support research participation in Parkinson’s disease: a mixed methods protocol

BMJ open, 2023-12, Vol.13 (12), p.e078638

2023

Volltextzugriff (PDF)

Investigating trial design variability in trials of disease-modifying therapies in Parkinson’s disease: a scoping review protocol

BMJ open, 2023-12, Vol.13 (12), p.e071641-e071641

2023

Volltextzugriff (PDF)

Identification of high-performing antibodies for the reliable detection of Tau proteoforms by Western blotting and immunohistochemistry

Acta neuropathologica, 2024-06, Vol.147 (1), p.87, Article 87

2024

Volltextzugriff (PDF)

109 Embedding patient voice in trial design: the EJS ACT-PD experience

Journal of neurology, neurosurgery and psychiatry, 2022-09, Vol.93 (9), p.e2

2022

Volltextzugriff (PDF)

Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson’s Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer

Journal of Parkinson's disease, 2020, Vol.10 (2), p.413-428

2020

Volltextzugriff (PDF)

233 Working towards an adaptive trial platform for Parkinson’s disease

Journal of neurology, neurosurgery and psychiatry, 2022-06, Vol.93 (6), p.A80-A81

2022

Volltextzugriff (PDF)

Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis

Oncotarget, 2016-07, Vol.7 (29), p.46603-46614

2016

Volltextzugriff (PDF)

Clinical trial designs and endpoints

Handbook of Clinical Neurology, 2024, Vol.205, p.123-134

2024

Volltextzugriff (PDF)

Developing a protocol to evaluate patient and care partner engagement in the EJS ACT-PD initiative

Journal of neurology, neurosurgery and psychiatry, 2023-11, Vol.94 (Suppl 1), p.A60-A61

2023

Volltextzugriff (PDF)

Outcome Measures for Disease-Modifying Trials in Parkinson's Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative

Journal of Parkinson's disease, 2023-01, Vol.13 (6), p.1011-1033

2023

Volltextzugriff (PDF)

Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes

Diabetologia, 2016-11, Vol.59 (11), p.2448-2458

2016

Volltextzugriff (PDF)

Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson’s disease

Brain (London, England : 1878), 2023-07, Vol.146 (7), p.2717-2722

2023

Volltextzugriff (PDF)

A novel rat CVB1-VP1 monoclonal antibody 3A6 detects a broad range of enteroviruses

Scientific reports, 2018-01, Vol.8 (1), p.33-33, Article 33

2018

Volltextzugriff (PDF)

Mapping UK Parkinson’s disease clinical research capability for the EJS ACT-PD initiative

Journal of neurology, neurosurgery and psychiatry, 2023-11, Vol.94 (Suppl 1), p.A61-A61

2023

Volltextzugriff (PDF)

[DELTA]9-TETRAHYDROCANNABINOL IS PROTECTIVE THROUGH PPAR[GAMMA] DEPENDENT MITOCHONDRIAL BIOGENESIS IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE

Journal of neurology, neurosurgery and psychiatry, 2013-11, Vol.84 (11), p.e2

2013

Volltextzugriff (PDF)

Δ9–TETRAHYDROCANNABINOL IS PROTECTIVE THROUGH PPARγ DEPENDENT MITOCHONDRIAL BIOGENESIS IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE

Journal of neurology, neurosurgery and psychiatry, 2013-11, Vol.84 (11), p.e2-e2

2013

Volltextzugriff (PDF)

Delta 9-TETRAHYDROCANNABINOL IS PROTECTIVE THROUGH PPAR gamma DEPENDENT MITOCHONDRIAL BIOGENESIS IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE

Journal of neurology, neurosurgery and psychiatry, 2013-11, Vol.84 (11), p.e2-be-e2

2013

Volltextzugriff (PDF)

Towards a multi-arm, multi-stage trial for disease modification in Parkinson’s: The EJS ACT-PD initiative

Journal of neurology, neurosurgery and psychiatry, 2023-11, Vol.94 (Suppl 1), p.A61-A61

2023

Volltextzugriff (PDF)

An evaluation of the potentially neuroprotective properties of cannabinoids in a cell culture model of parkinson's disease

Zeissler, Marie-Louise

2013

Volltextzugriff (PDF)

1 – 22 von 22

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(14)

Publikationsform

Artikel
(21)
Dissertationen
(1)

Sprache

Englisch
(22)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Embedding Patient Input in Outcome Measures for Long‐Term Disease‐Modifying Parkinson Disease Trials

An International Multi-Stakeholder Delphi Survey Study on the Design of Disease Modifying Parkinson’s Disease Trials

Incorporating usability evaluation into iterative development of an online platform to support research participation in Parkinson’s disease: a mixed methods protocol

Investigating trial design variability in trials of disease-modifying therapies in Parkinson’s disease: a scoping review protocol

Identification of high-performing antibodies for the reliable detection of Tau proteoforms by Western blotting and immunohistochemistry

109 Embedding patient voice in trial design: the EJS ACT-PD experience

Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson’s Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer

233 Working towards an adaptive trial platform for Parkinson’s disease

Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis

Clinical trial designs and endpoints

Developing a protocol to evaluate patient and care partner engagement in the EJS ACT-PD initiative

Patient and Public Involvement and Engagement in the Development of a Platform Clinical Trial for Parkinson’s Disease: An Evaluation Protocol

Outcome Measures for Disease-Modifying Trials in Parkinson's Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative

Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes

Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson’s disease

A novel rat CVB1-VP1 monoclonal antibody 3A6 detects a broad range of enteroviruses

Mapping UK Parkinson’s disease clinical research capability for the EJS ACT-PD initiative

[DELTA]9-TETRAHYDROCANNABINOL IS PROTECTIVE THROUGH PPAR[GAMMA] DEPENDENT MITOCHONDRIAL BIOGENESIS IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE

Δ9–TETRAHYDROCANNABINOL IS PROTECTIVE THROUGH PPARγ DEPENDENT MITOCHONDRIAL BIOGENESIS IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE

Delta 9-TETRAHYDROCANNABINOL IS PROTECTIVE THROUGH PPAR gamma DEPENDENT MITOCHONDRIAL BIOGENESIS IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE

Towards a multi-arm, multi-stage trial for disease modification in Parkinson’s: The EJS ACT-PD initiative

An evaluation of the potentially neuroprotective properties of cannabinoids in a cell culture model of parkinson's disease

Suchergebnisse filtern